The Supreme Court unanimously held in Hikma v. Amarin that induced infringement requires affirmative steps, not foreseeable or passive statements. The ruling raises the pleading bar for brand owners and extends beyond pharmaceutical skinny labels.
Supreme Court unanimously reversed the Federal Circuit in Hikma v. Amarin, ruling that 'skinny label' generic marketing does not induce patent infringement absent active steps to encourage it. The decision requires affirmative conduct, not mere plausible interpretations, to support inducement claims.
Two retrospective studies in type 2 diabetes patients with unruptured intracranial aneurysms linked GLP-1RAs to lower non-traumatic subarachnoid haemorrhage risk. One study also showed lower all-cause mortality over five years.
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07797335 |
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications |
RECRUITING | PHASE3 |
